DUBLIN, April 20, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology (AAN) annual meeting taking place April 22-28, 2017 in Boston. Among the highlights are three podium presentations on Chronic Migraine disease awareness and post-stroke spasticity in adults, and poster presentations in Alzheimer’s Disease. Additionally, two platform presentations showcasing findings from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study were identified as advances in the field of neuroscience and selected for a special session entitled, “Invited Science: Headache.” This session will include six 20-minute lectures highlighting some of the most exciting advances in the headache field.

“Allergan is extremely proud of the breadth of data being presented at AAN as it demonstrates our commitment to high quality research and development in neurology,” said David Nicholson, executive vice president and president of Global R&D Brands at Allergan. “We are also honored that the AAN Science Committee has selected two of our CaMEO studies as part of its special session on headaches. It is a true affirmation of our efforts to advance the science of migraine through ongoing research and clinical investment.”

The scheduled times (noted in local Eastern Time) of the presentations and locations at the Boston Convention and Events Center are as follows:

Chronic Migraine:

“Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”

Program Speaker: Ann Scher, PhD

PL8, Invited Science: Headache

Mon, 4/24, 3:30-5:30pm

“Perspectives of Adolescents on the Burden of their Parent’s Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”

Program Speaker: Richard Lipton, MD, FAAN

PL8, Invited Science: Headache

Mon, 4/24, 3:30-5:30

“Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL”

Authors: Blumenfeld A, Stark R, Adams A, Orejudos A, Aurora S

Poster #178, Session: P2: Headache: Clinical trials and Therapeutics

Mon, 4/24, 8:30am-7:00pm

“Epidemiology of Migraine in Men: Disease Presentation and Comorbidities from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study”

About AllerganAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.